(以下内容从万联证券《医药生物行业快评报告:阿斯利康与石药集团在AI制药方面达成合作,关注AI制药、创新药》研报附件原文摘录)事件:6月13日,阿斯利康与石药集团达成战略研究合作。双方将共同针对高优先级靶点展开合作,旨在推进可用于治疗多种疾病的新型口服候选药物的发现与开发,此次交易结构为“预付款+里程碑付款+销售分成”。投资要点:双方基于AI制药展开合作,预付款1.1亿美元。阿斯利康与石药集团将...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.